tariffs — Lanton Law Blog

Executive Action Targets High Drug Costs: What the Industry Needs to Know

On April 15, 2025, President Trump signed the executive order titled “Lowering Drug Prices by Once Again Putting Americans First,” signaling a significant shift in U.S. pharmaceutical policy. This directive aims to reduce prescription drug costs through a multifaceted approach, impacting various aspects of the healthcare industry.

Ron LantonApril 22, 2025Lowering Drug Prices by Once Again Putting Americans First, Executive Order, Medicare Price Negotiation, HHS, FDA, tariffs, imports

Lanton Law Speaks with Pharmaceutical Executive on Navigating NIH Funding Cuts, Diversity Bans, and Tariff Challenges

Lanton Law spoke with Pharmaceutical Executive on NIH Funding cuts. The interview is titled “Navigating NIH Funding Cuts, Diversity Bans, and Tariff Challenges: Legal and Industry Implications for Medical Research”

NIH, healthcare, HHS, life sciences, CongressRon LantonMarch 3, 2025NIH, clinical trials, FDA, CMS, Congress, tariffs, National Institutes of Health